Retatrutide and Tirzepatide are supplied strictly as laboratory research materials. They are not approved, intended or authorised for human consumption in this context, and nothing below is medical advice or dosing guidance. This comparison is written for qualified researchers evaluating reference compounds.
The core difference: three receptors vs two
Both molecules belong to the incretin class, but they pull different levers. Tirzepatide (LY3298176) is a dual agonist — it activates the GIP and GLP-1 receptors. Retatrutide (LY3437943) is a triple agonist: it hits GIP and GLP-1 as well, then adds a third arm — the glucagon receptor. That extra receptor is the whole story of why researchers are so interested in the newer compound. For the mechanistic detail, our explainer on GLP-1 vs GIP vs glucagon agonists breaks down what each receptor contributes.
Why the glucagon arm matters
Glucagon has a reputation as the hormone that raises blood glucose, so adding it to a weight-loss compound sounds counter-intuitive. The nuance is that glucagon-receptor agonism also increases resting energy expenditure and drives hepatic lipid mobilisation. Paired with the appetite-suppressing GLP-1/GIP action, the working model is that Retatrutide reduces energy intake and nudges energy output — a combination the dual agonists do not offer. That dual mechanism is the leading explanation for the larger effect size seen in early trials.
The trial numbers, side by side
Headline results are the reason this comparison exists. In the Phase 2 TRIUMPH-1 program, Retatrutide produced roughly 24.2% mean body-weight reduction at the highest dose over 48 weeks — and, notably, the curve had not plateaued. Tirzepatide's pivotal Phase 3 SURMOUNT-1 trial reported around 22.5% at its top dose over 72 weeks. The caveat every researcher should hold onto: these are different trial phases, durations and populations, so the figures are indicative rather than a clean apples-to-apples race.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Developer code | LY3437943 | LY3298176 |
| Mechanism | Triple agonist (GIP / GLP-1 / glucagon) | Dual agonist (GIP / GLP-1) |
| Key trial | TRIUMPH-1 (Phase 2) | SURMOUNT-1 (Phase 3) |
| Peak weight reduction | ~24.2% | ~22.5% |
| Approx. half-life | ~6 days | ~5 days |
| Regulatory status | Investigational | FDA-approved (Mounjaro / Zepbound) |
| Presentation | Lyophilised powder | Lyophilised powder |
Pharmacokinetics: half-life and handling
The two compounds are close on paper. Retatrutide carries an approximate 6-day half-life versus roughly 5 days for Tirzepatide — both long enough to support once-weekly dosing schedules in the studies. In the lab they behave almost identically: each ships as a sterile lyophilised (freeze-dried) powder in a sealed vial and is reconstituted with bacteriostatic water before use. Storage and reconstitution protocols are effectively interchangeable, which makes swapping a reference compound between experiments straightforward.
Regulatory status: investigational vs approved
This is the sharpest practical divide. Tirzepatide is an approved medicine — marketed as Mounjaro and Zepbound following FDA clearance — which means it comes with a deep, peer-reviewed safety and efficacy record. Retatrutide remains investigational: not approved or authorised for human use anywhere, and still moving through late-stage trials. For research purposes both are legitimately supplied and purchased as reference reagents for in vitro laboratory work, but the maturity of the underlying evidence base is very different, and that should inform how you frame any findings.
What it means for research
If your work centres on a well-characterised, heavily documented incretin comparator, Tirzepatide's approved status and Phase 3 dataset make it the steadier reference point. If you are investigating the frontier of the class — triple agonism, the glucagon-receptor contribution, or the energy-expenditure angle — Retatrutide is the compound generating the questions worth asking, precisely because so much about it is still being established. Many labs keep both on hand: one as the validated benchmark, the other as the object of study.
Which for your work?
There is no universal winner — the answer depends on the question you are asking. Choose Tirzepatide when you need a robust, approved comparator with mature data behind it. Choose Retatrutide when the triple-agonist mechanism and its larger early signal are the point of the experiment. For the deeper dive, our evergreen Retatrutide vs Tirzepatide guide unpacks the receptor pharmacology in full, and you can view live pricing on the buy Retatrutide UK and buy Tirzepatide UK pages.